Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.

ASHLAND A weight loss clinic with multiple locations in Kentucky, including Ashland, is facing accusations of providing ...

Northern Ireland will open its first specialist weight management service next year, which will provide access to obesity drugs such as glucagon-like peptide-1 receptor agonists, health minister Mike ...

Amble Health's website states it is a platform connecting patients to licensed healthcare professionals online, who can ...

Oral delivery of proteins and peptides has historically faced significant technical barriers due to the enzymatic degradation and poor permeability of macromolecules in the gastrointestinal (GI) tract ...

More than a dozen lawsuits have been filed on behalf of weight-loss drug users who claim that popular weight-loss medications ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...